Zacks Investment Research upgraded shares of SANUWAVE Health (SNWV) from NEUTRAL to OUTPERFORM on May 16, 2013, with a target price of $1.60.
In May 2012 FDA gave the green-light to SNWV's proposed IDE Supplement and add'l clinical trial. With treatment boosts, the trial could show endpoint-hitting efficacy. Important to understand is that this is not a replacement trial but is instead a supplement in every sense of the word – this supplemental data will be in addition to and build on the already very strong and compelling initial trial data. Enrollment for supplemental trial now expected in Q2 2013. Recent progress also includes new CEO brought on in early 2013 with incentive-laden contract, $2MM+ in new financing, game-plan to expand ex-U.S. distribution, investigating derivative applications of technology for possible out-licensing. We remain big believers in dermaPACE and SNWV's management. If all goes well dermaPACE could be on the U.S. mrkt in 2015.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on SANUWAVE Health (SNWV),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment